Dublin, June 26, 2019 (GLOBE NEWSWIRE) -- The "INOpulse" report has been added to ResearchAndMarkets.com's offering.
INOpulse (Bellerophon Therapeutics) is a drug-device combination being developed to deliver a continuous, pulsed dose of nitric oxide via intranasal inhalation. The INOpulse delivery system utilizes a technology to deliver pulsatile inhaled nitric oxide, allowing for use in a portable chronic setting.
Analyst Outlook
Bellerophon Therapeutics is developing INOpulse (nitric oxide), a unique drug-device combination that allows for the continuous inhalation of nitric oxide, a well-known vasodilator. The company has hit a roadblock with INOpulse's development for World Health Organization (WHO) group 1 pulmonary arterial hypertension (PAH) due to a recommendation from the data monitoring committee stating that its Phase III trial should be halted for futility.
While Bellerophon plans on analyzing the full dataset for PAH, it is likely that the company will be relying on its Phase II development program for WHO group 3 pulmonary hypertension (PH) due to lung disease for alternative success. The drug may possess greater opportunities and commercial prospects in the WHO group 3 patient segment, which is associated with critical unmet need with an absence of approved treatment options.
In contrast, Bellerophon's niche Phase III clinical program for PAH was targeting a restricted subset of patients with high disease burden who were on long-term oxygen therapy (LTOT). Moreover, the PAH segment is already highly saturated with approved therapies, further limiting INOpulse's potential impact on the market through its targeting of PAH
Key Topics Covered:
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
For more information about this report visit https://www.researchandmarkets.com/r/51kw7g
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Cardiovascular Drugs , Cardiovascular Devices